Latest available resultsQuarter ended June 30, 202610-Q · August 3, 2026
Filed with the SECBOSTON SCIENTIFIC CORP
BSXHealthcare
Next reportOctober 28, 2026pre-market · Analyst forecast 0.813 $/share
Revenue
$5.44B
▲ +7.5% vs prior year% YoY
Net income
$905.00M
▲ +13.8% vs prior year% YoY
EPS
0.61$
▲ +15.1% vs prior year% YoY
Net margin
16.6%
▲ +0.9 percentage points vs prior year pp YoY
Revenue▲ +7.5 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +13.8 %
EPS▲ +15.1 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $5.44B | |
| Gross profit | $3.85B | 70.7 % |
| Operating income | $1.18B | 21.6 % |
| Net income | $905.00M | 16.6 % |
| R&D | — | never filed |
| EPS (diluted) | 0.61 $ | |
| Balance sheet | ||
| Assets | $45.22B | |
| Liabilities | $20.04B | |
| Equity | $25.17B | |
| Cash | $539.00M | |
| Capital | ||
| Shares outstanding | 1.45B | as of 2026-07-30 |
| Public float | — | |